問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳立宗
下載
2019-04-01 - 2027-11-30
Condition/Disease
Test Drug
Participate Sites9Sites
Recruiting9Sites
2023-02-01 - 2027-06-30
Participate Sites4Sites
Recruiting4Sites
2018-10-01 - 2021-03-31
Participate Sites5Sites
Recruiting3Sites
Terminated1Sites
未分科
2022-04-01 - 2025-12-31
Participate Sites3Sites
2024-04-01 - 2028-01-31
Advanced/Metastatic Solid Tumors
injection
Participate Sites10Sites
Not yet recruiting1Sites
Recruiting8Sites
2022-03-01 - 2022-12-31
Participate Sites1Sites
Recruiting1Sites
2022-10-17 - 2023-10-26
2021-10-20 - 2023-11-02
2019-02-01 - 2019-12-25
Recruiting5Sites
2018-09-01 - 2022-12-31
Hepatocellular Carcinoma (HCC)
nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞
全部
